Status:
UNKNOWN
Expression and Role of the JAK/STAT Pathway in Sarcoidosis Granuloma Cells
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Sarcoidosis
JAK-STAT Pathway Deregulation
Eligibility:
All Genders
18-80 years
Brief Summary
Recent studies suggest that the JAK/STAT signaling pathway constitutes a new step in the clinical and therapeutic progress of sarcoidosis. Further investigations are necessary to identify the most sui...
Detailed Description
The investigators hypothesize that the JAK/STAT signaling pathway constitutes a new step in the clinical and therapeutic progress of sarcoidosis, in particular in cases of severe sarcoidosis refractor...
Eligibility Criteria
Inclusion
- Patients with a diagnosis of mediastinopulmonary sarcoidosis made according to ATS / ERS / WASOG criteria
- Or patient suspected of having mediastino-pulmonary sarcoidosis, without any other probable causal factor identified on the usual standard examination at the time of the sample with the need for diagnostic confirmation at the end of the study according to the criteria of the ATS / ERS / WASOG
- Sarcoidosis with stage 1 to 4 pulmonary involvement
- Patients who had a chest CT scan in the 6 months preceding the sample. Examination carried out as part of routine care
Exclusion
- Pregnancy.
- Opposition expressed to participation in the study.
- Patients on State Medical Aid.
Key Trial Info
Start Date :
March 9 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 2 2024
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT04751279
Start Date
March 9 2021
End Date
January 2 2024
Last Update
November 18 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Service de pneumologie Hôpital Avicenne
Bobigny, France, 93000